| NCT ID | NCT06885918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ALS Therapy Development Institute |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2014-09-12 |
| Primary Completion | 2035-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2014-09-12 with a primary completion date of 2035-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this natural history study is to learn more about the biological and clinical aspects of amyotrophic lateral sclerosis (ALS). This study's findings will help with drug discovery, biomarker discovery, and outcome measure validation. Adults living with ALS, other motor neuron diseases (MND), a known mutation related to ALS and healthy volunteers contribute prospective and retrospective data to this study remotely. The study is sponsored and conducted by the ALS Therapy Development Institute.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Can communicate in written English * Has a diagnosis of ALS/MND or is a known carrier of an ALS associated mutation Exclusion Criteria: * Significant cognitive impairment that would prevent individual completion and understanding of the informed consent process.
Contact & Investigator
Fernando G Vieira, M.D.
PRINCIPAL INVESTIGATOR
ALS Therapy Development Institute
Frequently Asked Questions
Who can join the NCT06885918 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06885918 currently recruiting?
Yes, NCT06885918 is actively recruiting participants. Contact the research team at apremasiri@als.net for enrollment information.
Where is the NCT06885918 trial being conducted?
This trial is being conducted at Watertown, United States.
Who is sponsoring the NCT06885918 clinical trial?
NCT06885918 is sponsored by ALS Therapy Development Institute. The principal investigator is Fernando G Vieira, M.D. at ALS Therapy Development Institute. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.